Bavarian plans to send RSV vaccine to phase III, prepares equity raise

A commitment to initiate a phase III study of its vaccine candidate against the RS virus in the first half of 2022 has led Bavarian Nordic to prepare a share issue involving up to 10 percent of its registered capital.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic has committed to initiating a phase III study of its vaccine against RSV in the first half of 2022. However, sufficient funding must first be secured through a fundraising round where 10 percent of registered share capital is up for grabs, the company reports in a press release.

Bavarian Nordic will incur additional costs of approximately DKK 30 million (USD 4.5m) in 2021 as it prepares for the trial.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs